Denali Therapeutics (DNLI) Income from Continuing Operations (2017 - 2024)
Historic Income from Continuing Operations for Denali Therapeutics (DNLI) over the last 8 years, with Q4 2024 value amounting to -$114.7 million.
- Denali Therapeutics' Income from Continuing Operations rose 400.76% to -$114.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$422.7 million, marking a year-over-year decrease of 19107.1%. This contributed to the annual value of -$422.8 million for FY2024, which is 19111.79% down from last year.
- As of Q4 2024, Denali Therapeutics' Income from Continuing Operations stood at -$114.7 million, which was up 400.76% from -$107.2 million recorded in Q3 2024.
- Over the past 5 years, Denali Therapeutics' Income from Continuing Operations peaked at $244.9 million during Q4 2020, and registered a low of -$119.5 million during Q4 2023.
- In the last 5 years, Denali Therapeutics' Income from Continuing Operations had a median value of -$79.9 million in 2021 and averaged -$55.7 million.
- Per our database at Business Quant, Denali Therapeutics' Income from Continuing Operations soared by 55328.09% in 2020 and then tumbled by 15399.96% in 2024.
- Over the past 5 years, Denali Therapeutics' Income from Continuing Operations (Quarter) stood at $244.9 million in 2020, then crashed by 130.73% to -$75.3 million in 2021, then crashed by 31.11% to -$98.7 million in 2022, then fell by 21.07% to -$119.5 million in 2023, then increased by 4.01% to -$114.7 million in 2024.
- Its Income from Continuing Operations stands at -$114.7 million for Q4 2024, versus -$107.2 million for Q3 2024 and -$99.0 million for Q2 2024.